⚠️ Disclaimer: This article contains information about DMT, a controlled substance in many jurisdictions. It is intended for educational and research purposes only. Nothing here constitutes legal, medical, or therapeutic advice. Always consult qualified professionals and verify local laws before any use.
Key Facts (June 2026)
- Psychedelic therapeutics market: $2.94 billion in 2025, projected to reach $11.03 billion by 2034 (CAGR 15.82%) — Precedence Research, 2025
- Global tannin market: $2.98 billion in 2025, growing to $4.14 billion by 2030 (CAGR 6.8%) — Mordor Intelligence, 2025
- Brazil Amazon deforestation: Fell 11% to 5,796 km² in the 12 months ending July 2025 — lowest in 11 years (INPE/PRODES)
- DMT clinical trial result: 100% of patients in Phase 2a trial (NCT06094907) showed improvement vs. baseline; rapid onset within Day 1 — no serious adverse events reported
- Regulatory shift: Australia proposed Schedule 8A Controlled-Use category for DMT (2026); Alberta, Canada legalized DMT for therapeutic use; Colorado licensed facilities permitted to offer DMT from 2026
Mimosa hostilis (syn. Mimosa tenuiflora, known regionally as Jurema Preta) is a fast-growing thorny shrub native to the semi-arid Caatinga of northeastern Brazil. Its root bark contains high concentrations of N,N-Dimethyltryptamine (DMT), tannins, flavonoids, and phenolic compounds, making it one of the most commercially and scientifically consequential ethnobotanical species of the 21st century. As of 2026, the plant sits at the intersection of a $2.94 billion psychedelic therapeutics market, a $2.98 billion global tannin industry, and some of the most significant shifts in drug regulation seen in decades. The central challenge ahead is ensuring this rising global demand does not outpace the conservation and ethical frameworks needed to protect both the species and the indigenous communities who have stewarded it for centuries.
What Is Mimosa Hostilis? (Definition)
Mimosa hostilis is a perennial leguminous shrub (family Fabaceae) native to the semi-arid northeast of Brazil. Also known scientifically as Mimosa tenuiflora and regionally as Jurema Preta, it grows to 4–8 meters in height and is notable for high concentrations of N,N-Dimethyltryptamine (DMT) in its root bark — typically 0.31–1.25% by dry weight — alongside tannins (up to 16%), lupeol, saponins, and flavonoids. It has been used by indigenous Brazilian communities for centuries in ceremonial, medicinal, and textile applications.
DMT (N,N-Dimethyltryptamine) is a naturally occurring indole alkaloid and serotonin receptor agonist found in dozens of plant species worldwide. In pharmacological terms, DMT acts primarily on 5-HT2A serotonin receptors, producing profound short-duration alterations in perception and consciousness. It is classified as a Schedule I substance in the United States and a Schedule 9 prohibited substance in Australia, though several jurisdictions — including Alberta (Canada) and Colorado (USA) — introduced regulated therapeutic access frameworks in 2023–2026.
MHRB (Mimosa Hostilis Root Bark) refers specifically to the bark harvested from the root system of M. hostilis, which contains the highest concentration of DMT and tannins in the plant. Harvesting MHRB requires uprooting or killing the tree, making it significantly more ecologically destructive than stem bark harvesting.
Cutting-Edge Research: Phytochemistry and Clinical Trials
Supercritical CO₂ Extraction (December 2025)
A peer-reviewed study published in Natural Product Research (received March 2025; published December 6, 2025, DOI: 10.1080/14786419.2025.2596353) demonstrated the first characterization of M. tenuiflora bioactive compounds using supercritical CO₂ — a solvent-free, pharmaceutical-grade extraction method. Extractions were performed at 314–328 K and 8–22 MPa, with CO₂ flow rates of 40–50 mL/min over 90 minutes. HPLC-MS, NMR, UV-Vis, and FTIR analysis confirmed DMT as the major compound. The study also found significant surface-active properties in the extract (assessed via Ross-Miles foam testing and drop-volume surface tension measurement at 308.15 K), suggesting novel applications in pharmaceutical delivery systems and cosmetic emulsification — well beyond the compound’s known neuropsychiatric uses.
This method represents a meaningful advance over traditional organic solvent extraction (dichloromethane, chloroform, n-butanol), which leaves impurities, requires hazardous chemical handling, and produces extracts of unknown toxicological composition.
Phase 2a Clinical Trial: Vaporized DMT for Treatment-Resistant Depression
The most clinically significant recent development is the first formal trial of vaporized DMT in treatment-resistant depression (TRD). This open-label, fixed-order, dose-escalation Phase 2a study (ClinicalTrials.gov ID: NCT06094907) was approved by the Ethics Committee of the University Hospital Onofre Lopes (HUOL) in Brazil (approval #45532421.0.0000.5292). Participants were patients experiencing moderate-to-severe depressive episodes (MADRS ≥ 20 for at least four weeks) who had failed at least two prior antidepressant medications. All enrolled patients showed improvement in depression severity scores (MADRS and PHQ-9) at Day 1, Day 7, Day 14, and Month 1 compared to baseline. No serious adverse events were recorded. The rapid onset of effects — significant improvement within 24 hours of dosing — aligns with the emerging class of rapid-acting antidepressants and distinguishes DMT from conventional pharmacotherapy.
This trial is the foundation for growing pharmaceutical interest in M. hostilis-derived compounds. The broader psychedelic therapeutics sector — which includes psilocybin, MDMA, ketamine, and DMT — was valued at $2.94 billion in 2025 and is projected by Precedence Research (2025) to reach $11.03 billion by 2034 at a CAGR of 15.82%. The depression segment alone captured more than 57% of market share in 2024.
Beyond DMT: Emerging Phytochemical Research
Advanced profiling continues to expand the known pharmacological potential of M. hostilis beyond its signature alkaloid. Flavonoids, phenolic acids, and condensed tannins isolated from root and stem bark show measurable anti-inflammatory and antioxidant activity in pre-clinical studies. These findings support ongoing research into potential applications in neuroinflammation, chronic pain, and dermatological wound healing — areas the December 2025 supercritical extraction paper also flagged as priorities.
Conservation: Where Things Stand in 2026
Brazil’s Improving — but Fragile — Conservation Picture
At the macro level, habitat conditions for Mimosa hostilis have improved. Brazil’s National Institute for Space Research (INPE) reported in its PRODES satellite assessment that Amazon deforestation in the 12 months ending July 2025 fell 11% to 5,796 km² — the lowest annual total in 11 years. Brazil’s new National Biodiversity Strategy and Action Plan (NBSAP 2025–2030), published in January 2026 and aligned with the Kunming–Montreal Global Biodiversity Framework, commits to conserving 80% of the Amazon biome by 2030.
However, M. hostilis is native not primarily to the Amazon but to the Caatinga — Brazil’s semi-arid northeastern scrubland — which faces its own distinct pressures: charcoal production, agricultural clearing for livestock, and urban encroachment. Conservation protections in this biome are less developed than in the Amazon, and local extirpation of M. hostilis from over-harvesting of MHRB is a documented and ongoing risk despite the species holding no global endangered status.
The Harvesting Problem: Root Bark vs. Stem Bark
The most urgent conservation challenge is structural. MHRB commands the highest market prices because it contains the highest alkaloid concentrations, but obtaining it destroys the plant entirely. Stem bark harvesting — which leaves the tree alive to regenerate — is ecologically preferable but commercially underutilized because it yields lower DMT concentrations. Shifting commercial sourcing standards toward stem bark and cultivated supply is one of the highest-leverage conservation interventions available.
Ex Situ Cultivation and Agroforestry
Researchers and commercial growers have demonstrated reliable propagation via vegetative cuttings treated with auxin-based rooting hormones, tissue culture protocols, and certified seed orchards — all of which produce consistent yields without depleting wild populations. Integrating M. hostilis into agroforestry systems alongside native nitrogen-fixing legumes and fruit trees provides farmers additional revenue while maintaining soil health and biodiversity. Rotational harvesting with a 3–5 year cycle between harvests on any given plot is the current standard recommendation.
Commercial grower best practices (2026):
| Parameter | Recommendation |
|---|---|
| Soil | Well-drained, sandy, pH 5.5–7.5 |
| Propagation method | Cuttings with auxin-based rooting hormone |
| Preferred harvest | Stem bark (not MHRB) to preserve plant viability |
| Plot rotation | 3–5 years between harvests |
| Certification | Fair-trade or organic marking for premium market access |
| Traceability | Record cultivation site, harvest date, yield per batch |
The Regulatory Landscape in 2026: A Jurisdiction-by-Jurisdiction Breakdown
Regulation of DMT — and by extension Mimosa hostilis root bark — is shifting faster in 2025–2026 than in any prior period. Here is the verified current status:
| Jurisdiction | Current DMT Status | Key 2025–2026 Development |
|---|---|---|
| Brazil | Traditional ceremonial use protected; commercial DMT production requires ANVISA licensing | NBSAP 2025–2030 strengthens habitat protections |
| USA (Federal) | Schedule I (prohibited outside research) | No federal change; state-level reform active |
| Colorado, USA | Decriminalized for adults 21+; licensed facilities can offer DMT from 2026 | Prop 122 framework expansion took effect |
| Canada (Federal) | Schedule I under CDSA; medical/research exemptions available | 2024 amendment streamlined clinical trial licensing; modest increase in approved DMT studies |
| Alberta, Canada | Legal for therapeutic use | First Canadian province to legalize DMT for therapy |
| Australia | Schedule 9 (prohibited) | Proposed Schedule 8A Controlled-Use category for select psychedelics including DMT; parliamentary consideration ongoing as of mid-2026 |
| Switzerland | Special physician permissions for psychedelic-assisted therapy | Continues leading EU-area access |
Non-psychoactive applications of Mimosa hostilis — natural dyes, tannin extraction for leather and cosmetics, bioplastic precursors — face minimal regulatory restriction in any jurisdiction and represent the lowest-friction commercial pathway globally.
Market Opportunities: The Tannin and Industrial Value Stack
The commercial case for M. hostilis extends well beyond DMT. Tannin — the plant’s second most commercially significant compound class — is a global commodity with robust industrial demand.
The global tannin market was valued at $2.98 billion in 2025 and is projected to grow to $4.14 billion by 2030 at a CAGR of 6.8%, according to Mordor Intelligence (2025). Natural tannin extracts — including mimosa bark — dominate the market, holding approximately 72% of global source share in 2025, driven by demand for plant-derived, biodegradable alternatives to synthetic chromium-based tanning agents (Data Bridge Market Research, 2025). In the leather sector alone, tannins account for approximately 55% of total raw material usage globally as of 2025 (Coherent Market Insights, 2025).
Key non-psychedelic applications of M. hostilis:
- Natural dyes: Tannin-rich bark produces stable, eco-friendly dyes used in textiles, wood stains, and specialty inks — no regulatory restriction in any major market
- Cosmetics and skincare: Antioxidant and polyphenolic fractions appear in anti-aging formulations, wound-healing balms, and organic skincare; the December 2025 supercritical study validated additional surface-active properties relevant to emulsification
- Bioplastic precursors: Condensed tannins are used as sustainable alternatives in resin and polymer production, meeting growing EU sustainability directive requirements; Södra (Sweden) announced in April 2025 a new production line specifically for bark-derived tannin extraction for leather processing
Ethical Obligations: Indigenous Rights and Benefit-Sharing
Indigenous and traditional communities across northeastern Brazil — particularly those of the Jurema Preta ceremonial tradition — have used Mimosa hostilis for centuries in healing, ritual, and craft contexts. Their knowledge underlies much of what the global market now monetizes.
Ethical compliance requires, at minimum:
- Free, Prior, and Informed Consent (FPIC) before commercializing any knowledge derived from traditional use, consistent with Brazil’s obligations under the Nagoya Protocol on Access and Benefit-Sharing (ratified 2021)
- Equitable benefit-sharing agreements that direct royalties and capacity-building resources to originating communities — not just symbolic acknowledgment
- Certified cultivated sourcing as a structural commitment, rather than treating wild-harvesting as a default fallback
- Transparent royalty and licensing structures that are publicly documented and auditable
In February 2026, Brazil’s Supreme Federal Court issued an order governing Indigenous land use and requiring free, prior, and informed consultation with affected communities before any resource extraction — reinforcing the legal ground for these obligations.
Challenges and Future Directions
Genetic Erosion and Wildcrafting Quotas
Unregulated MHRB wildcrafting remains the primary ecological threat to the long-term viability of M. hostilis as a commercially harvestable species. Without harvesting quotas grounded in population viability analyses (PVA), local gene pools risk erosion even as the species retains global non-threatened status. Investment in seed banks and genetic repositories — analogous to those maintained for food crops under the Svalbard system — represents a long-term insurance policy against localized extinction events.
CRISPR and Precision Cultivation Research
Cross-disciplinary research consortia spanning pharmacologists, ethnobotanists, and agricultural scientists are exploring targeted cultivation techniques including CRISPR-assisted trait selection — not to engineer new compounds, but to select for naturally higher-alkaloid populations and improved drought resilience under climate-shifted Caatinga conditions. These efforts remain pre-commercial but are advancing in academic research settings.
Consumer Labeling Standards
As product diversity expands from raw bark to processed extracts, natural dyes, cosmetics, and bioplastic feedstocks, labeling clarity becomes both a trust signal and a regulatory compliance requirement. Emerging best-practice standards include:
- Botanical origin: Wild-harvested vs. cultivated; harvest region and year
- Extraction method: Solvent type or solvent-free (supercritical); yield percentage; temperature range
- Compound profile: Quantitative DMT, bufotenin, tannin percentage by dry weight
- Certifications: Fair-trade, organic, or ethical sourcing marks where applicable
Conclusion
The future of Mimosa hostilis is being written simultaneously in clinical trial registries, legislative chambers, tannin market reports, and the Caatinga itself. As of mid-2026, the evidence points in a cautiously optimistic direction: Phase 2a clinical data supports the therapeutic potential of DMT-derived compounds; Brazil’s deforestation rate is at an 11-year low; the global tannin market for plant-derived extracts is growing at 6.8% annually; and regulatory frameworks in Canada, Australia, and Colorado are creating structured pathways for therapeutic access. The risks — genetic erosion from wildcrafting, inconsistent indigenous benefit-sharing, and the pace of regulation lagging behind commercial demand — are real and require active management, not passive optimism. The organizations and researchers who navigate this intersection of science, conservation, and ethics most rigorously will define what this remarkable species means to the world over the next decade.
Frequently Asked Questions
What is Mimosa hostilis used for?
Mimosa hostilis (syn. Mimosa tenuiflora, Jurema Preta) is used primarily for three purposes: (1) as a source of DMT (N,N-Dimethyltryptamine) for psychedelic-assisted therapy research and traditional ceremonial use; (2) as a tannin source for natural leather processing, textile dyes, and wood finishes; and (3) in cosmetic and skincare formulations for its antioxidant and anti-inflammatory compound profile. A December 2025 study in Natural Product Research also identified surface-active properties in supercritical CO₂ extracts, suggesting additional pharmaceutical delivery applications.
Is Mimosa hostilis legal in 2026?
Legality depends heavily on jurisdiction and intended use. In the United States, DMT remains a federal Schedule I substance, but Colorado’s Proposition 122 framework permits its use in licensed therapeutic facilities starting 2026, and personal possession is decriminalized for adults 21+. In Canada, DMT is Schedule I federally, but Alberta has legalized it for therapeutic use and Health Canada’s 2024 amendment streamlined clinical trial licensing. In Australia, DMT is a Schedule 9 prohibited substance, though proposed 2026 reforms may create a regulated “Controlled-Use” Schedule 8A category. Non-psychoactive applications (dyes, tanning, cosmetics) face no DMT-related restrictions in any major jurisdiction.
What did the 2025 Mimosa hostilis research study find?
A December 2025 peer-reviewed study (Natural Product Research, DOI: 10.1080/14786419.2025.2596353) used supercritical CO₂ extraction on Mimosa tenuiflora root bark and confirmed DMT as the major bioactive compound using HPLC-MS and NMR analysis. The study additionally found significant surface-active properties — relevant to foaming and emulsification — in the extracts, indicating potential pharmaceutical delivery and cosmetic applications beyond DMT’s established neuropsychiatric profile.
What were the results of the DMT clinical trial for depression?
A Phase 2a clinical trial (NCT06094907) evaluating vaporized DMT in treatment-resistant depression (TRD) — conducted at the University Hospital Onofre Lopes, Brazil, and registered at ClinicalTrials.gov — found that all enrolled patients showed improvement in depression severity (MADRS and PHQ-9 scores) at Day 1, Day 7, Day 14, and Month 1 compared to baseline. No serious adverse events were reported. This is the first clinical trial specifically on the antidepressant effects of vaporized DMT in TRD patients.
How big is the market for Mimosa hostilis products?
The two largest market contexts are: (1) the global psychedelic therapeutics market, valued at $2.94 billion in 2025 and projected to reach $11.03 billion by 2034 at a CAGR of 15.82% (Precedence Research, 2025), where DMT-derived compounds represent a growing segment; and (2) the global tannin market, valued at $2.98 billion in 2025 and expected to grow to $4.14 billion by 2030 at a CAGR of 6.8% (Mordor Intelligence, 2025), where mimosa bark tannins compete alongside quebracho and chestnut sources for the leather and industrial chemicals sectors.
How can Mimosa hostilis be grown sustainably?
Sustainable cultivation relies on: (1) ex situ propagation using vegetative cuttings with auxin-based rooting hormones, tissue culture, and seed orchards to reduce wild harvesting pressure; (2) agroforestry integration, interplanting with native legumes and fruit trees to support biodiversity and soil health; (3) rotational harvesting on a 3–5 year cycle with plot rotation; and (4) preferring stem bark over destructive MHRB harvesting wherever the intended application allows. Traceability records (site, date, yield) are increasingly a prerequisite for fair-trade and ethical sourcing certification.
What are the ethical obligations for companies using Mimosa hostilis?
Under the Nagoya Protocol (to which Brazil is a signatory) and Brazilian law, commercial use of knowledge derived from indigenous traditional use requires: free, prior, and informed consent (FPIC) from originating communities; equitable benefit-sharing agreements directing royalties to local communities; and transparent licensing structures. Brazil’s Supreme Federal Court reinforced these requirements in a February 2026 ruling on indigenous resource consultation. Companies sourcing MHRB should also commit structurally to cultivated supply rather than wild harvesting as their primary sourcing pathway.
